Recent Updates — ASND
On October 26, 2026, Ascendis Pharma announced new data from its Phase 2 PaTH Forward and Phase 3 PaTHway trials demonstrating early, sustained improvements in kidney function for adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) for up to five years. A pooled analysis of 139 patients showed a mean estimated glomerular filtration rate (eGFR) improvement of 7.2 mL/min/1.73 m² by Week 26 and 9.6 mL/min/1.73 m² by Week 52, with eGFR remaining stable through the end of the trials. By Week 52, 68.9% of patients achieved a clinically meaningful eGFR increase of at least 5 mL/min/1.73 m², and 49.6% saw an increase greater than 10 mL/min/1.73 m². Additionally, 98% of patients achieved independence from active vitamin D, and 95% from therapeutic calcium doses, with no new safety signals identified. Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending marketing authorization for Ascendis Pharma's once-weekly TransCon CNP (navepegritide). The recommendation covers treatment for achondroplasia in children aged two and older with open epiphyses. This decision follows a review of clinical data from three randomized, double-blind, placebo-controlled trials and up to three years of open-label extension data. The final European Commission decision is expected during the fourth quarter of 2026. If authorized, Ascendis expects its first EU launch under the brand name YUVIWEL in Germany during the first quarter of 2027. Ascendis Pharma A/S operates as a biopharmaceutical company focused on developing therapies for rare diseases.
The board of directors granted an aggregate of 35,890 warrants to certain employees under the Company’s Articles of Association. Each warrant confers the right to subscribe for one ordinary share with an exercise price equal to US $223.21 per share, reflecting the closing price on the grant date. Vesting is structured such that 25% vests on the one-year anniversary, while the remaining 75% vests monthly at a rate of 1/36th thereafter, subject to continued service and potential acceleration upon exit events. Following this issuance, warrants for an additional 1,459,173 shares remain available for future grants. Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases.
On September 29, 2026, the exercise window for outstanding warrants closed. The Company registered aggregate share capital increases of nominal DKK 210,812 through the issuance of 210,812 ordinary shares against average cash consideration of approximately USD $123.36 per share. This increased total share capital to nominal DKK 66,400,738 and amended the articles of association. Ascendis Pharma A/S operates in the biotechnology industry, focusing on the development of therapies for rare diseases.
On September 14, 2026, Ascendis Pharma announced it will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows the termination of its collaboration agreement with Novo Nordisk A/S, previously announced in November 2024. Under the agreement terms, all licenses granted to Novo Nordisk for these indications revert to Ascendis, and neither party has continuing financial obligations to the other. Ascendis Pharma is a biopharmaceutical company focused on developing transformative therapies for serious diseases.
On September 14, 2026, the Board of Directors authorized a new share repurchase program allowing the company to buy back up to $400 million of ordinary shares. Purchases may be executed through open market transactions, privately negotiated deals, block trades, accelerated share repurchases, or 10b5-1 plans at management's discretion based on market conditions and share price. The program does not mandate a specific number of shares and can be modified, suspended, or terminated without notice. Ascendis Pharma A/S is a biotechnology company focused on developing therapies for rare diseases.